Teva Pharmaceutical Industries logged a -1.0% change during today's morning session, and is now trading at a price of $9.16 per share.
Teva Pharmaceutical Industries returned gains of 14.0% last year, with its stock price reaching a high of $11.45 and a low of $7.09. Over the same period, the stock underperformed the S&P 500 index by -9.0%. As of April 2023, the company's 50-day average price was $9.77. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. Based in Tel Aviv, Israel, the large-cap Health Care company has 34,004 full time employees. Teva Pharmaceutical Industries has not offered a regular dividend during the last year.
Exceptional Profitability Overshadowed by Excessive Leverage:
| 2018-02-01 | 2019-02-19 | 2020-02-21 | 2021-02-10 | 2022-02-09 | 2023-02-10 | |
|---|---|---|---|---|---|---|
| Revenue (MM) | $22,385 | $18,271 | $16,887 | $16,659 | $15,878 | $14,925 |
| Gross Margins | 47.0% | 45.0% | 45.0% | 46.0% | 48.0% | 47.0% |
| Operating Margins | 18% | 16% | 16% | 18% | 20% | 18% |
| Net Margins | -73.0% | -12.0% | -6.0% | -24.0% | 3.0% | -16.0% |
| Net Income (MM) | -$16,265 | -$2,150 | -$999 | -$3,990 | $416 | -$2,353 |
| Net Interest Expense (MM) | -$895 | -$959 | -$822 | -$834 | -$1,058 | -$966 |
| Depreciation & Amort. (MM) | -$2,112 | -$1,842 | -$1,722 | -$1,557 | -$1,330 | -$1,308 |
| Earnings Per Share | -$16.26 | -$2.35 | -$0.92 | -$3.64 | $0.38 | -$2.12 |
| EPS Growth | n/a | 85.55% | 60.85% | -295.65% | 110.44% | -657.89% |
| Diluted Shares (MM) | 1,016 | 1,021 | 1,091 | 1,095 | 1,109 | 1,110 |
| Free Cash Flow (MM) | $3,099 | $1,362 | $930 | $1,727 | $1,049 | $2,070 |
| Capital Expenditures (MM) | -$874 | $1,084 | -$182 | -$511 | -$251 | -$480 |
| Net Current Assets (MM) | -$36,488 | -$31,095 | -$28,942 | -$26,575 | -$23,851 | -$23,264 |
| Long Term Debt (MM) | $28,829 | $26,700 | $24,562 | $22,731 | $21,617 | $19,103 |
| Net Debt / EBITDA | 5.16 | 5.76 | 5.61 | 5.14 | 4.71 | 4.61 |
Teva Pharmaceutical Industries does not have a meaningful trailing P/E ratio since its earnings per share are currently in the red. Based on its EPS guidance of $2.45, the company has a forward P/E ratio of 4.0. In comparison, the average P/E ratio for the Health Care sector is 24.45. On the other hand, the market is undervaluing Teva Pharmaceutical Industries in terms of its equity because its P/B ratio is 1.46. In comparison, the sector average is 4.16.
Teva Pharmaceutical Industries Has an Analyst Consensus of Some Upside Potential:
The 9 analysts following Teva Pharmaceutical Industries have set target prices ranging from $8.0 to $14.0 per share, for an average of $10.56 with a hold rating. As of April 2023, the company is trading -7.5% away from its average target price, indicating that there is an analyst consensus of some upside potential.
The largest shareholder is Blackrock Inc., whose 4% stake in the company is worth $369,054,625.
